Early sorafenib induction after transarterial chemoembolization for unresectable hepatocellular carcinoma: Can sorafenib after TACE improve loco‑regional control?

  • Authors:
    • Tsutomu Tamai
    • Kotaro Kumagai
    • Haruka Sakae
    • Hiroka Onishi
    • Kazuaki Tabu
    • Eriko Tabu
    • Kaori Muromachi
    • Akiko Saishoji
    • Kohei Oda
    • Seiichi Mawatari
    • Akihiro Moriuchi
    • Kazuhiro Sakurai
    • Akio Ido
  • View Affiliations

  • Published online on: October 2, 2017     https://doi.org/10.3892/mco.2017.1434
  • Pages:1135-1141
0

Abstract

This prospective study aimed to estimate the efficacy of sorafenib therapy after transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (HCC). Between July 2011 and March 2013, 17 patients were enrolled, 11 of whom received sorafenib therapy. Patients who previously received TACE for HCC and whose disease progressed within a six‑month period were given 400‑800 mg sorafenib orally, once or twice daily, within the 3 weeks after a second TACE (sorafenib after TACE group). The response to treatment, time to progression (TTP), overall survival (OS), and adverse events (AEs) were recorded. Of the 113 patients who underwent initial TACE for unresectable HCC between January 1995 and January 2013, 23 patients were selected who were treated with TACE alone, and for whom the interval between the second and third TACE treatments was <6 months (TACE alone group). The interval (TTP) was calculated between the third and fourth TACE treatments, then TTP was compared among the three groups: Sorafenib after TACE for > or <4 months; and TACE alone. During a median follow‑up period of 34.4 months (range, 5.9‑51.7 months) in both groups receiving sorafenib after TACE, sorafenib prolonged TTP (3.9 months) and OS (34.4 months). It was demonstrated that sorafenib use for >4 months prolonged TTP (5.7 months) significantly compared with use for <4 months (3.0 months) (P=0.002). The OS of patients given sorafenib for >4 months (35.9 months) was longer than that of patients who received the drug for <4 months (17.2 months), but this difference was not significant. In the TACE alone group, the median TTP between the third and fourth TACE treatments was 4.3 months. TTP decreased among the groups in the following order: Sorafenib for >4 months, TACE alone, and sorafenib for <4 months. There were three AEs of grade 3 in the present study. Two patients demonstrated a decrease in liver reserve function following sorafenib treatment, but improved immediately after sorafenib administration was stopped. Sorafenib induction early after TACE for unresectable HCC was generally well tolerated and significantly improved TTP. Further studies are required to confirm the safety and efficacy of this combination therapy.

Related Articles

Journal Cover

December 2017
Volume 7 Issue 6

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Tamai, T., Kumagai, K., Sakae, H., Onishi, H., Tabu, K., Tabu, E. ... Ido, A. (2017). Early sorafenib induction after transarterial chemoembolization for unresectable hepatocellular carcinoma: Can sorafenib after TACE improve loco‑regional control?. Molecular and Clinical Oncology, 7, 1135-1141. https://doi.org/10.3892/mco.2017.1434
MLA
Tamai, T., Kumagai, K., Sakae, H., Onishi, H., Tabu, K., Tabu, E., Muromachi, K., Saishoji, A., Oda, K., Mawatari, S., Moriuchi, A., Sakurai, K., Ido, A."Early sorafenib induction after transarterial chemoembolization for unresectable hepatocellular carcinoma: Can sorafenib after TACE improve loco‑regional control?". Molecular and Clinical Oncology 7.6 (2017): 1135-1141.
Chicago
Tamai, T., Kumagai, K., Sakae, H., Onishi, H., Tabu, K., Tabu, E., Muromachi, K., Saishoji, A., Oda, K., Mawatari, S., Moriuchi, A., Sakurai, K., Ido, A."Early sorafenib induction after transarterial chemoembolization for unresectable hepatocellular carcinoma: Can sorafenib after TACE improve loco‑regional control?". Molecular and Clinical Oncology 7, no. 6 (2017): 1135-1141. https://doi.org/10.3892/mco.2017.1434